International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

…, ED Bateman, EH Bel, ER Bleecker… - European respiratory …, 2014 - Eur Respiratory Soc
Severe or therapy-resistant asthma is increasingly recognised as a major unmet need. A
Task Force, supported by the European Respiratory Society and American Thoracic Society, …

Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program

…, WW Busse, SC Erzurum, ER Bleecker - American journal of …, 2010 - atsjournals.org
Rationale: The Severe Asthma Research Program cohort includes subjects with persistent
asthma who have undergone detailed phenotypic characterization. Previous univariate …

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

ID Pavord, S Korn, P Howarth, ER Bleecker, R Buhl… - The Lancet, 2012 - thelancet.com
Background Some patients with severe asthma have recurrent asthma exacerbations
associated with eosinophilic airway inflammation. Early studies suggest that inhibition of …

The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol

HS Nelson, ST Weiss, ER Bleecker, SW Yancey… - Chest, 2006 - Elsevier
Study objective To compare the safety of salmeterol xinafoate or placebo added to usual
asthma care. Design A 28-week, randomized, double-blind, placebo-controlled, observational …

Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a …

ER Bleecker, JM FitzGerald, P Chanez, A Papi… - The Lancet, 2016 - thelancet.com
Background Eosinophilia is associated with worsening asthma severity and decreased lung
function, with increased exacerbation frequency. We assessed the safety and efficacy of …

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a …

JM FitzGerald, ER Bleecker, P Nair, S Korn, K Ohta… - The Lancet, 2016 - thelancet.com
Background Benralizumab is a humanised, afucosylated, anti-interleukin-5 receptor α
monoclonal antibody that induces direct, rapid, and nearly complete depletion of eosinophils. We …

[HTML][HTML] Genetic susceptibility to asthma—bronchial hyperresponsiveness coinherited with a major gene for atopy

DS Postma, ER Bleecker, PJ Amelung… - … England Journal of …, 1995 - Mass Medical Soc
Background Bronchial hyperresponsiveness, a risk factor for asthma, consists of a
heightened bronchoconstrictor response to a variety of stimuli. The condition has a heritable …

Characterization of the severe asthma phenotype by the national heart, lung, and blood institute's severe asthma research program

WC Moore, ER Bleecker, D Curran-Everett… - Journal of Allergy and …, 2007 - Elsevier
BACKGROUND: Severe asthma causes the majority of asthma morbidity. Understanding
mechanisms that contribute to the development of severe disease is important. OBJECTIVE: …

Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma

…, N Aït-Khaled, CE Baena-Cagnani, ER Bleecker… - Journal of Allergy and …, 2010 - Elsevier
Asthma is a global health problem affecting around 300 million individuals of all ages, ethnic
groups and countries. It is estimated that around 250,000 people die prematurely each year …

[HTML][HTML] Meta-analysis of genome-wide association studies of asthma in ethnically diverse North American populations

…, JE Gern, RF Lemanske, TH Beaty, ER Bleecker… - Nature …, 2011 - ncbi.nlm.nih.gov
Asthma is a common disease with a complex risk architecture including both genetic and
environmental factors. We performed a meta-analysis of North American genome-wide …